FDA warns of foot, leg amputations with Invokana

0
Shares

Patients with type 2 diabetes taking Johnson & Johnson’s drug Invokana are twice as likely to have a leg and foot amputation than patients given a placebo, two clinical trial show.

The FDA recently required J&J to add a black box warning, reserved for the most serious possible adverse events, to Invokana (Invoking, Invokanmet and Invokamet XR) also known as canagliflozin.

Invokana is also subject to litigation for another serious side effect, severe kidney damage.

Read attorney Jamie Sheller’s blog post on The Legal Examiner regarding Invokana’s new black box warning.

Previous blog post on Invokana:FDA Warnings on SGLT2 Diabetes Drugs.

Previous post

High Court Won't Hear Sheller Dispute with FDA over Risperdal

Next post

Sheller Represents IVC Filter Victims Nationwide